Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
14 studies found for:    LAM | Open Studies | NIH, U.S. Fed
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC
Condition: Lymphangioleiomyomatosis (LAM)
Intervention: Drug: Celecoxib
2 Recruiting Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
Condition: Lymphangioleiomyomatosis
Interventions: Drug: albuterol inhaler;   Procedure: PFT;   Drug: albuterol nebulizer
3 Recruiting Study of the Disease Process of Lymphangioleiomyomatosis
Conditions: Lung Disease;   Pneumothorax;   Tuberous Sclerosis
Intervention:
4 Recruiting Safety and Durability of Sirolimus for Treatment of LAM
Condition: Lymphangioleiomyomatosis
Interventions: Drug: Sirolimus;   Drug: Everolimus
5 Not yet recruiting Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial
Condition: Dyspnea
Intervention: Drug: Sirolimus
6 Recruiting Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis
Condition: Pulmonary Lymphangioleiomyomatosis
Intervention: Drug: saracatinib
7 Recruiting VA MERIT: A Comparative Efficacy Study: Treatment of Non-Healing Diabetic Foot Ulcers
Condition: Diabetic Foot Ulcer
Interventions: Device: SECONDARY dressing gauze and tape;   Procedure: debridement, irrigation;   Device: Dermagraft™;   Device: Oasis™
8 Recruiting Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
Conditions: Metastatic Transitional Cell Carcinoma;   Metastatic Urothelial Carcinoma;   Recurrent Bladder Carcinoma;   Stage III Bladder Urothelial Carcinoma;   Stage IV Bladder Urothelial Carcinoma;   TSC1 Gene Mutation;   TSC2 Gene Mutation
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Sapanisertib
9 Not yet recruiting Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Advanced Refractory Solid Tumors or Lymphomas
Conditions: Histiocytic Sarcoma;   Juvenile Xanthogranuloma;   Langerhans Cell Histiocytosis;   Lymphoma;   Recurrent Central Nervous System Neoplasm;   Recurrent Malignant Solid Neoplasm;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm
Interventions: Drug: ALK Inhibitor X-396;   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Other: Laboratory Biomarker Analysis;   Procedure: Mutation Carrier Screening;   Drug: Olaparib;   Other: Pharmacological Study;   Drug: PI3K/mTOR Inhibitor LY3023414;   Drug: Selumetinib Sulfate;   Drug: Tazemetostat;   Drug: Trk Inhibitor LOXO-101;   Drug: Vemurafenib
10 Recruiting Deuterated Phenanthrene Tetraol in Smokers Who Are at High Risk For Lung Cancer
Conditions: Lung Cancer;   Squamous Lung Dysplasia;   Tobacco Use Disorder
Interventions: Radiation: deuterated phenanthrene tetraol;   Other: pharmacological study;   Other: laboratory biomarker analysis
11 Recruiting Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
Conditions: Colorectal Adenocarcinoma;   KRAS wt Allele;   NRAS wt Allele;   Stage IV Colorectal Cancer;   Stage IVA Colorectal Cancer;   Stage IVB Colorectal Cancer
Interventions: Biological: Bevacizumab;   Biological: Cetuximab;   Drug: Irinotecan;   Other: Laboratory Biomarker Analysis;   Other: Placebo
12 Recruiting International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)
Conditions: Cardiovascular Diseases;   Coronary Disease;   Coronary Artery Disease;   Heart Diseases;   Myocardial Ischemia
Interventions: Procedure: cardiac catheterization;   Procedure: coronary artery bypass graft surgery;   Procedure: percutaneous coronary intervention;   Behavioral: Lifestyle;   Drug: Medication
13 Not yet recruiting The International Diabetes Closed Loop (iDCL) Trial: Main Protocol
Condition: Type1 Diabetes Mellitus
Interventions: Device: Artificial Pancreas;   Other: Sensor Augmented Therapy;   Device: continuous glucose monitor (CGM)
14 Recruiting International Diabetes Closed Loop (iDCL) Trial: Research Site Training Protocol
Condition: Diabetes Mellitus, Type 1
Intervention: Device: Artificial Pancreas

Study has passed its completion date and status has not been verified in more than two years.